Ikena Oncology Operating Margin 2021-2025 | IMA
Current and historical operating margin for Ikena Oncology (IMA) over the last 10 years. The current operating profit margin for Ikena Oncology as of March 31, 2025 is 0.00%.
| Ikena Oncology Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2023-12-31 |
$0.01B |
$-0.08B |
-844.44% |
| 2023-09-30 |
$0.01B |
$-0.07B |
-530.77% |
| 2023-06-30 |
$0.02B |
$-0.07B |
-372.22% |
| 2023-03-31 |
$0.02B |
$-0.07B |
-437.50% |
| 2022-12-31 |
$0.01B |
$-0.07B |
-507.14% |
| 2022-09-30 |
$0.03B |
$-0.05B |
-182.76% |
| 2022-06-30 |
$0.03B |
$-0.05B |
-185.19% |
| 2022-03-31 |
$0.03B |
$-0.04B |
-135.48% |
| 2021-12-31 |
$0.03B |
$-0.04B |
-112.90% |
| 2021-09-30 |
$0.01B |
$-0.07B |
-654.55% |
| 2021-06-30 |
$0.01B |
$-0.06B |
-630.00% |
| 2021-03-31 |
$0.01B |
$-0.06B |
-611.11% |
| 2020-12-31 |
$0.01B |
$-0.05B |
-577.78% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.061B |
$0.009B |
|
Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States.
|
